CollPlant Biotechnologies has successfully regained compliance with Nasdaq listing criteria, bolstered by its recent acquisition of LightSolver, enhancing its position in biotechnology and photonics.

YouTube video by Gelbart Kahana

Reported Tuesday, Sep 22 - 7:32am EDT (TheFly subscription required to read more.)

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

The transaction included a $5 million investment in LightSolver, upfront shares and pre-funded warrants, with more warrants tied to technology and commercial objectives.

Collagen Gelatin Regenerative Medicine Market is projected to register a CAGR of 9.78% to reach USD 9.22 Billion by the end of 2035, Market Product Type, Application

CollPlant Biotechnologies invites investors to its LightSolver webinar on September 17, 2026, unveiling innovations in photonic computing.

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

CollPlant Biotechnologies has appointed Dr. Ruti Ben Shlomi, CEO of LightSolver, to its Board of Directors after acquiring the company, enhancing photonic computing initiatives.

Reported Friday, Sep 4 - 8:32am EDT (TheFly subscription required to read more.)

CollPlant Biotechnologies (CLGN) appointed Dr. Ruti Ben Shlomi, CEO and Co‑Founder of LightSolver, to its Board of Directors, effective immediately following the completion of CollPlant's acquisition of LightSolver announced on September 3, 2026.LightSolver develops a proprietary Laser Processing Unit (LPU), an all‑optical, energy‑efficient photonic computing platform designed to accelerate computationally intensive workloads in scientific simulation, engineering, optimization and Physical AI. CollPlant states that Dr. Ben Shlomi's deep expertise in photonic computing and entrepreneurship will support the commercialization of this newly acquired technology.With the LightSolver acquisition, CollPlant expands from regenerative medicine into advanced high‑performance computing, aiming to address demanding workloads in aerospace, defense and Physical AI while continuing its collagen-based 3D bioprinting, tissue repair and medical aesthetics activities.

LightSolver Founder and CEO brings deep scientific and entrepreneurial expertise to CollPlant's Board as the Company advances the commercialization of its newly acquired photonic computing technology REHOVOT, Israel, Sept. 4, 2026 /PRNewswire/ -- CollPlant Biotechnologies Ltd. (Nasdaq:...

Reported Thursday, Sep 3 - 7:50pm EDT (TheFly subscription required to read more.)

CollPlant has successfully completed the acquisition of LightSolver, marking its entry into photonic computing and high-performance computing sectors.

Reported Thursday, Sep 3 - 8:13am EDT (TheFly subscription required to read more.)

Technological Edge - LightSolver advances the development of the world's first Laser Processing Unit (LPU) – an energy-efficient, pure photonic computing platform Accelerated Growth Path - The transaction positions LightSolver to accelerate its path towards commercialization and expand...

Financial terms of deal have not been disclosed

CollPlant (Nasdaq: CLGN) announced that its board has approved a one-for-ten reverse share split of its ordinary shares, following shareholder approval at the August 18, 2026 extraordinary general meeting. The split will take effect at the opening of trading on September 4, 2026, when CLGN will begin trading on a split-adjusted basis.According to CollPlant, the reverse split is part of its strategic plan to regain compliance with Nasdaq’s minimum bid price requirement. Fractional shares will be rounded to the nearest whole share, and all outstanding options and warrants will be proportionately adjusted. The new CUSIP will be M2R51X124.

Reported Tuesday, Sep 1 - 4:03pm EDT (TheFly subscription required to read more.)